In the U.S., diagnostic errors contribute to an estimated 371,000 deaths each year, more than the annual toll from stroke. For Aidoc, a New York-based startup, this statistic is the foundation of its business. Founded in 2016 by Elad Walach, Michael Braginsky, and Guy Reiner, Aidoc is building an AI-driven platform that aims to reduce those diagnostic lapses by embedding clinical intelligence directly into healthcare workflows.
The company just announced a $150 million funding round co-led by General Catalyst and Square Peg, with participation from NVIDIA’s NVentures and four major U.S. health systems: Hartford HealthCare, Mercy, Sutter Health, and WellSpan. The round brings Aidoc’s total funding to $370 million and includes a $40 million revolving credit facility. The capital will be used to scale up CARE, Aidoc’s new clinical-grade foundation model, and aiOS, its AI operating system for hospital systems.
Deploying Clinical AI Infrastructure
Aidoc’s aiOS platform serves as an enterprise-grade system that allows hospitals to deploy, monitor, and measure multiple AI models across departments. Of the hospitals currently using Aidoc, the company says 69% are also running third-party models on aiOS. The system supports real-time notifications, integrates with EHRs and scheduling tools, and enables cross-functional care coordination with minimal disruption, according to the company.
This strategy has been validated by traction in the market. Aidoc reports that its platform currently supports more than 45 million patient cases annually across over 150 health systems. Its partners include large institutions such as Mount Sinai, Yale New Haven, and Northwell Health. The company aims to double that reach to 100 million patients within three years.
The key to that scale is CARE, the company’s foundation model trained on multimodal clinical data. CARE powers Aidoc’s new generation of diagnostic and triage tools and, according to the company, accelerates the development of new applications by a factor of 20. Two CARE-powered tools have already received FDA clearance, and Aidoc plans to migrate all of its 18 existing cleared models to the new foundation.
Strategic partnerships with NVIDIA and AWS will underwrite this technical expansion. NVIDIA’s investment came after two years of technical collaboration, and the companies are now working to define implementation standards for clinical AI. Aidoc has also committed to spending more than $150 million to develop and deploy CARE in partnership with the two firms.
Hospitals as Investors, Not Just Customers
One notable element of Aidoc’s recent raise is the participation of four U.S. health systems as strategic investors. Their support may reflect growing comfort among providers with AI’s potential to reduce physician workload and accelerate care delivery.
Jeffrey Flaks, CEO of Hartford HealthCare, said the health system’s experience with Aidoc “reflects our commitment to advancing AI in a safe, scalable and thoughtful way.” WellSpan Health’s CEO, Roxanna Gapstur, noted that Aidoc helped radiologists at her system analyze more than 200,000 cases in a single year, reducing delays in high-risk diagnoses.
Aidoc’s vision is ambitious, and long-term execution will be critical. Regulatory oversight is intensifying for Clinical AI, and interoperability across systems is a persistent challenge. Braginsky acknowledged the risk: “Scaling clinical AI is an enormous lift,” he said. “Success isn’t guaranteed, but we believe we’re in a unique position to bring this vision to life.”
